12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Envoy Therapeutics, Takeda deal

Takeda will acquire partner Envoy for up to $140 million in cash, including an upfront payment and preclinical milestones. Takeda, which has a 12.5% stake in Envoy, will gain the biotech's bacTRAP technology and preclinical CNS assets, which include programs for Parkinson's disease (PD) and cognitive...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >